Recent

% | $
Quotes you view appear here for quick access.

Novartis AG Message Board

crazyness42003 1 post  |  Last Activity: May 17, 2015 12:53 PM Member since: Feb 18, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • (Reuters) - The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization.

    The FDA, in a warning on its website, said the medicines may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones.

    The oral drugs belong to a class known as SGLT2 inhibitors that work by causing blood sugar to be secreted in the urine. They include AstraZeneca's Farxiga (dapagliflozin), J&J's Invokana (canagliflozin) and Jardiance (embagliflozin) from Lilly and Boehringer
    The medicines became popular in part because in addition to controlling blood sugar levels, they led to modest weight loss and slightly lower blood pressure. Obesity is a leading cause of type 2 diabetes and some older treatments cause weight gain.

    But the new FDA warning could help boost sales of alternative medicines, such as ..........

NVS
103.75+0.57(+0.55%)Jul 31 4:03 PMEDT